Pack Coil Ignition for 03-17 Pontiac Isuzu GMC Express Chevrolet Cadillac Buick Car & Truck Ignition Coils, Modules & Pick-Ups


  1. Home
  2. Pack Coil Ignition for 03-17 Pontiac Isuzu GMC Express Chevrolet Cadillac Buick
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Ignition Coil Pack for Buick Cadillac Chevrolet Express GMC Isuzu Pontiac 03-17
Condition: New Brand:

Unbranded

Make2: Hummer, Pontiac, Saab, WorkHorse Manufacturer Part Number:

UF-413, 12611424, 12570616, H6T552712C

Model 1: Express 2500, Express Pasajeros, Impala, Monte Carlo Interchange Part Number: UF413, 12611424, 12570616, H6T552712C
Model 2: Silverado 3500, Silverado 3500 HD, SSR, Tahoe, Trailblazer Other Part Number: UF-413, 12611424, 12570616, H6T552712C
Model 3: Allure, LaCrosse, Rainer, CTS, Escalade, Suburban 1500 Warranty: 1 Year
Year: 2003-2017 Fitment Type: Direct Replacement
Engine: V8 4.8L, V8 5.3L, V8 5.7L, V8 6.0L, V8 6.2L, V8 7.0L Compatible Makes: Buick, Cadillac, Chevrolet, GMC, Isuzu
UPC:

Does not apply











published on tue nov 09 2021

Pack Coil Ignition for 03-17 Pontiac Isuzu GMC Express Chevrolet Cadillac Buick Car & Truck Ignition Coils, Modules & Pick-Ups

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Pack Coil Ignition for 03-17 Pontiac Isuzu GMC Express Chevrolet Cadillac Buick Car & Truck Ignition Coils, Modules & Pick-Ups

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS